Life Sciences Nova Scotia
  • About
    • Who We Are
    • What we do
    • Why work in Nova Scotia?
    • Contact us
  • Members
    • Member Directory
    • Member Benefits
    • Member In Focus
    • Become a member
  • Resources
    • Member Programs
    • News and success stories
    • PetriDish Job Board
  • Events
    • Events
    • BioPort Atlantic
    • Atlantic Precision Medicine Conference
  • Podcast
Select Page

First Patient Dosed in Phase 1 Clinical Trial Evaluating Neoepitopes Formulated in IMV’s DPX Delivery Platform in Ovarian Cancer Patients

by administrator | Jan 17, 2019 | IMV Inc., Members, News

Read original release here January 17, 2019 at 7:05 AM EST DARTMOUTH, Nova Scotia, Jan. 17, 2019 (GLOBE NEWSWIRE) — IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that the first patient has been treated in the...

Recent Posts

  • Sona Nanotech To Arrange Private Placement Financing
  • Nova Scotia femtech startup Elle MD raises $1.1 million
  • Celebrating a Year of Impact and Momentum at Our 2026 AGM
  • 3DBioFibR and FinLeaf Technologies Recognized at Startupfest 2026
  • Manufacturing the Future of Life‑Saving Medicine in Nova Scotia
No comments to show.
[buddybot_chat id=1]

Life Sciences Nova Scotia is the organization to help fuel your success.

Join today
  • WHO WE ARE
  • EVENTS
  • MEMBER PROGRAMS
  • CONTACT US
  • MEMBERS
  • NEWS & SUCCESS STORIES
  • Follow
  • Follow